

## **Shevington Pharma LTD**

Directors' Report and Unaudited

Financial Statements

Year Ended

31 December 2018

Company Number 07870252

THURSDAY



\*A8CWK4NE\*

A11

29/08/2019

#34

COMPANIES HOUSE

# Shevington Pharma LTD

## Company Information

---

**Directors**

Mrs A C Cheetham  
Dr C J Munro  
Dr A J Winstanley  
Dr M Pollard  
Dr L Mercer  
Dr L M Bose  
Dr C J Lancaster  
Dr D A Humphreys  
Dr S K Wilks

**Company secretary** Mrs A C Cheetham

**Registered number** 07870252

**Registered office**

1 Houghton Lane  
Shevington  
Wigan  
WN6 8ET

**Trading Address**

1 Houghton Lane  
Shevington  
Wigan  
WN6 8ET

**Accountants**

BDO LLP  
3 Hardman Street  
Spinningfields  
Manchester  
M3 3HF

# Shevington Pharma LTD

## Contents

---

	Page
Directors' Report	1
Accountants' Report	2
Statement of Comprehensive Income	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 12

# Shevington Pharma LTD

## Directors' Report For the Year Ended 31 December 2018

---

The directors present their report and the financial statements for the year ended 31 December 2018.

### Principal activity

The principal activity of the the company continued to be that of a management company.

### Directors

The directors who served during the year were:

Mrs A C Cheetham  
Dr C J Munro  
Dr A J Winstanley  
Dr M Pollard  
Dr L Mercer  
Dr L M Bose  
Dr C J Lancaster  
Dr D A Humphreys  
Dr S K Wilks

### Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board on

20.08.19

and signed on its behalf.

  
Dr C J Lancaster  
Director

# Shevington Pharma LTD

## Chartered Accountants' Report to the Board of Directors on the preparation of the Unaudited Financial Statements of Shevington Pharma LTD for the Year Ended 31 December 2018

---


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Shevington Pharma LTD for the year ended 31 December 2018 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at <http://www.icaew.com/en/members/regulations-standards-and-guidance/>.

This report is made solely to the board of directors of Shevington Pharma LTD, as a body, in accordance with the terms of our engagement letter dated 19 August 2019. Our work has been undertaken solely to prepare for your approval the accounts of Shevington Pharma LTD and state those matters that we have agreed to state to the board of directors of Shevington Pharma LTD, as a body, in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Shevington Pharma LTD and its board of directors as a body for our work or for this report.

It is your duty to ensure that Shevington Pharma LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Shevington Pharma LTD. You consider that Shevington Pharma LTD is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Shevington Pharma LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.



**BDO LLP**  
Chartered Accountants  
Manchester  
United Kingdom

27 August 2019

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

# Shevington Pharma LTD

## Statement of Comprehensive Income For the Year Ended 31 December 2018

	Note	2018 £	2017 £
Turnover		40,128	40,128
<b>Gross profit</b>		<b>40,128</b>	40,128
Administrative expenses		(50,608)	(51,517)
<b>Operating loss</b>		<b>(10,480)</b>	(11,389)
Income from shares in group undertakings		78,000	66,000
<b>Profit before tax</b>		<b>67,520</b>	54,611
Tax on profit		401	492
<b>Profit for the financial year</b>		<b>67,921</b>	55,103

There was no other comprehensive income for 2018 (2017:£NIL).

The notes on pages 6 to 12 form part of these financial statements.

All activities are derived from continuing operations.

**Shevington Pharma LTD**  
Registered number: 07870252

**Balance Sheet**  
**As at 31 December 2018**


	Note	2018 £	2017 £
<b>Fixed assets</b>			
Tangible assets	5	4,809	11,935
Investments	6	6	6
		<u>4,815</u>	<u>11,941</u>
<b>Current assets</b>			
Debtors: amounts falling due within one year	7	742	6,729
Cash at bank and in hand		88,664	142,375
		<u>89,406</u>	<u>149,104</u>
Creditors: amounts falling due within one year	8	(6,227)	(5,571)
<b>Net current assets</b>		<u>83,179</u>	<u>143,533</u>
<b>Total assets less current liabilities</b>		<u>87,994</u>	<u>155,474</u>
<b>Provisions for liabilities</b>			
Deferred tax		(143)	(544)
		<u>(143)</u>	<u>(544)</u>
<b>Net assets</b>		<u><u>87,851</u></u>	<u><u>154,930</u></u>
<b>Capital and reserves</b>			
Called up share capital		9	9
Profit and loss account		87,842	154,921
		<u>87,851</u>	<u>154,930</u>

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

  
Dr C J Lancaster  
Director

20.08.19

The notes on pages 6 to 12 form part of these financial statements.

# Shevington Pharma LTD

## Statement of Changes in Equity For the Year Ended 31 December 2018

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 January 2018	9	154,921	154,930
<b>Comprehensive income for the year</b>			
Profit for the year	-	67,921	67,921
<b>Other comprehensive income for the year</b>	-	-	-
<b>Total comprehensive income for the year</b>	-	67,921	67,921
Dividends: Equity capital	-	(135,000)	(135,000)
<b>Total transactions with owners</b>	-	(135,000)	(135,000)
<b>At 31 December 2018</b>	<b>9</b>	<b>87,842</b>	<b>87,851</b>

## Statement of Changes in Equity For the Year Ended 31 December 2017

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 January 2017	9	189,818	189,827
<b>Comprehensive income for the year</b>			
Profit for the year	-	55,103	55,103
<b>Other comprehensive income for the year</b>	-	-	-
<b>Total comprehensive income for the year</b>	-	55,103	55,103
Dividends: Equity capital	-	(90,000)	(90,000)
<b>Total transactions with owners</b>	-	(90,000)	(90,000)
<b>At 31 December 2017</b>	<b>9</b>	<b>154,921</b>	<b>154,930</b>

The notes on pages 6 to 12 form part of these financial statements.



# Shevington Pharma LTD

## Notes to the Financial Statements For the Year Ended 31 December 2018

---

### 1. General information

Shevington Pharma LTD is a private company, limited by shares, incorporated in England and Wales under the Companies Act. The address of the registered company is given on the contents page and the Company's principal activities are set out in the Directors Report.

### 2. Accounting policies

#### 2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies which can be seen in note 3.

The following principal accounting policies have been applied:

#### 2.2 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

##### Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

#### 2.3 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

# Shevington Pharma LTD

## Notes to the Financial Statements For the Year Ended 31 December 2018

---

### 2. Accounting policies (continued)

#### 2.3 Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures & fittings	- 15% straight line method
---------------------	----------------------------

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of Comprehensive Income.

#### 2.4 Valuation of investments

*Investments in subsidiaries are measured at cost less accumulated impairment.*

#### 2.5 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

#### 2.6 Financial instruments

Financial liabilities and equity are classified according to the substance of the financial instruments contractual obligations, rather than legal form.

The Company's cash at bank and in hand and trade and other debtors and its trade and other creditors are measured initially at the transaction price, including transaction cost, and subsequently at amortised cost using effective interest method. Debt instruments that are payable or receivable within one year are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.

#### 2.7 Creditors

Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Creditors are recognised initially at fair value and subsequently measured at amortised cost using effective interest method.

#### 2.8 Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. Dividends on shares recognised as liabilities are recognised as expenses and classified within interest payable.

# Shevington Pharma LTD

## Notes to the Financial Statements For the Year Ended 31 December 2018

---

### 2. Accounting policies (continued)

#### 2.9 Operating leases: the Company as lessor

Rentals income from operating leases is credited to the Statement of Comprehensive Income on a straight line basis over the term of the relevant lease.

#### 2.10 Operating leases: the Company as lessee

Rentals paid under operating leases are charged to the Statement of Comprehensive Income on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

#### 2.11 Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

### 3. Judgments in applying accounting policies and key sources of estimation uncertainty

In preparing these financial statements, the directors have had to make the following judgments:

- Determine whether leases entered into by the Company either as a lessor or a lessee are operating leases or finance leases. These decisions depend on an assessment of whether the risks and rewards of ownership have been transferred from the lessor to the lessee on a lease by lease basis.

# Shevington Pharma LTD

## Notes to the Financial Statements For the Year Ended 31 December 2018

### 4. Employees

The average monthly number of employees, excluding directors, during the year was 0 (2017 -0).

### 5. Tangible fixed assets

	Fixtures & fittings £
<b>Cost or valuation</b>	
At 1 January 2018	56,672
Additions	268
At 31 December 2018	<u>56,940</u>
<b>Depreciation</b>	
At 1 January 2018	44,737
Charge for the year	7,394
At 31 December 2018	<u>52,131</u>
<b>Net book value</b>	
At 31 December 2018	<u><u>4,809</u></u>
At 31 December 2017	<u><u>11,935</u></u>

# Shevington Pharma LTD

## Notes to the Financial Statements For the Year Ended 31 December 2018

### 6. Fixed asset investments

	Investments in subsidiary companies £
<b>Cost or valuation</b>	
At 1 January 2018	6
At 31 December 2018	6
<b>Net book value</b>	
At 31 December 2018	6
At 31 December 2017	6

### Subsidiary undertakings

The following were subsidiary undertakings of the Company:

Name	Class of shares	Holding	Principal activity
Shevington JV Limited	Ordinary	60 %	Pharmacy

The registered office of Shevington JV Limited is 1 Houghton Lane, Shevington, Wigan, Lancashire, WN6 8ET.

	Aggregate of share capital and reserves £	Profit/(loss) £
Shevington JV Limited	199,259	94,475
	<u>199,259</u>	<u>94,475</u>

# Shevington Pharma LTD

## Notes to the Financial Statements For the Year Ended 31 December 2018

### 7. Debtors

	2018 £	2017 £
Trade debtors	720	720
Other debtors	9	6,009
Prepayments and accrued income	13	-
	<u>742</u>	<u>6,729</u>

### 8. Creditors: Amounts falling due within one year

	2018 £	2017 £
Trade creditors	895	895
Other creditors	2,675	2,470
Accruals and deferred income	2,657	2,206
	<u>6,227</u>	<u>5,571</u>

### 9. Commitments under operating leases

At 31 December 2018 the Company had future minimum lease payments under non-cancellable operating leases as follows:

	2018 £	2017 £
Not later than 1 year	27,864	27,864
Later than 1 year and not later than 5 years	111,456	111,456
Later than 5 years	390,096	417,960
	<u>529,416</u>	<u>557,280</u>

### 10. Related party transactions

Shevington JV Limited is a subsidiary company. During the year, rental income of £27,864 (2017: £27,864), service charge income of £5,064 (2017: £5,064) and management fees of £7,200 (2017: £7,200) were received from Shevington JV Limited.

During the year, Shevington Pharma Limited received dividends from Shevington JV Limited, which totalled £78,000 (2017: £66,000).

There is a balance of £720 in trade debtors (£2017: £720 trade debtor, £6000 other debtors) relates to Shevington JV Limited.

# **Shevington Pharma LTD**

## **Notes to the Financial Statements For the Year Ended 31 December 2018**

---

### **11. Controlling party**

The Company is controlled by Houghton Lane Surgery.